Needham Reiterates Buy on Cogent Biosciences, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintained a price target of $16.
October 24, 2024 | 9:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Cogent Biosciences and maintained a price target of $16, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $16 price target by a reputable analyst suggests a positive outlook for Cogent Biosciences. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100